Amyloidosis

Despite the number of new medications produced to treat a range of neurologic diseases, limited utilization is driven by relatively high cost and similar efficacy to less expensive drugs, according to a study published in Neurology.

Evaluating efficacy and safety of patisiran (Onpattro, Alnylam) in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

In patients with transthyretin-mediated amyloidosis with cardiomyopathy, patisiran improved functional capacity and quality of life at 12 months compared with placebo, according to the results of the APOLLO-B trial.

Alnylam announced top-line results of a trial showing that patisiran improved 6-minute walk test distance in patients with transthyretin-mediated amyloidosis and cardiomyopathy.

The association between 24-hour collection and urine protein-to-creatinine ratio was moderate for mearing proteinuria levels in patients with amyloid light chain amyloidosis, according to data published in Kidney Medicine.

Patients admitted with HF with amyloidosis had a higher 30-day, all-cause readmission rate and longer hospital stay vs. HF patients without amyloidosis, study data presented at the American Heart Association Scientific Sessions show.

Common “red flag” comorbid conditions stored in the electronic health record often preceded the diagnosis of cardiac amyloidosis by years, according to a presentation from the American Heart Association Scientific Sessions.

The incidence of cardiac amyloidosis in the Danish population increased in the last 2 decades, translating to a potential increase in the global population, according to research published in JACC: CardioOncology.

The spectrum of conditions under the amyloidosis umbrella can present in myriad ways in patients with rheumatic diseases, with several possible complications, according to data from the 2021 Congress of Clinical Rheumatology-East.

Central arterial stiffening contributed to biomarker evidence of neuroinflammation and neurodegeneration in older adults, according to a community-based observational study published in Neurology.